Translated title of the contribution: Disseminated poor-risk neuroblastoma. Results of an 'intensive' protocol (AIEOP NB-85)

P. Corciulo, G. Deb, A. Mazzei, G. Bisogno, G. M. Surico, M. Tonello, A. Garaventa, A. Arrighini, F. Lumia, G. Zanazzo, D. Gallisai, F. Massolo, P. E. Cornelli, R. Targhetta, A. Di Cataldo, R. Ragusa, A. Acquaviva, G. Bernini, A. Fiorillo

Research output: Contribution to journalArticlepeer-review


From January 1985-November 1989, 106 children aged 1-15 years with newly diagnosed disseminated neuroblastoma were treated with an intensive chemotherapy protocol in 21 Italian institutions. Induction therapy included high dose (HD) peptichemio and cisplatin and was usually followed by the attempt at removing the primary tumor. Children who achieved complete (CR) or partial (PR) remission received consolidation therapy made of either 3 cycles of HD chemotherapy (3cCT), or one cycle of myeloablative therapy (MAT) followed by autologous bone marrow rescue. A 76% CR + PR rate was achieved after induction chemotherapy; 69% of children underwent radical resection of primary tumor. 5-yr overall survival is 27%, progression-free survival (PFS) is 18%; however, relapses were observed even after 5 years of follow-up. Median survival is 24 months. Children in CR after induction phase treated with 3cCT or MAT had similar PFS results (24% and 32%, respectively). Our data confirm that an intensified therapy provides a high CR + PR rate and prolonges survival of children with poor-risk disseminated neuroblastoma. However, the occurrance of late relapses makes the eventual outcome of these children still uncertain.

Translated title of the contributionDisseminated poor-risk neuroblastoma. Results of an 'intensive' protocol (AIEOP NB-85)
Original languageItalian
Pages (from-to)586-594
Number of pages9
JournalRivista Italiana di Pediatria
Issue number6
Publication statusPublished - 1993

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Disseminated poor-risk neuroblastoma. Results of an 'intensive' protocol (AIEOP NB-85)'. Together they form a unique fingerprint.

Cite this